A study using brain imaging and biomarker data identified three distinct patterns of cognitive decline in people with preclinical Alzheimer's disease.
Key Details
- 1Researchers analyzed 6-year data from the A4 and LEARN studies, involving people with preclinical Alzheimer's.
- 2Three cognitive trajectories were identified: stable, slow decline, and fast decline; 70% of participants remained stable.
- 3Higher baseline levels of phosphorylated tau (P-tau217) and brain scan tau markers, as well as smaller hippocampal volumes, predicted greater cognitive decline.
- 4Biomarker models could predict stable vs. declining status with about 70% accuracy.
- 5Findings suggest many clinical trial participants do not decline, complicating drug effect measurement.
Why It Matters
The study advances understanding of heterogeneity in Alzheimer's progression and highlights the potential for imaging biomarkers (e.g., PET, MRI) to inform prognosis and participant selection in clinical trials. Improved prediction via imaging and AI could optimize trial design and enable more personalized care in neurodegenerative disease.
Source
EurekAlert
Related News
•EurekAlert
AI-Enhanced Imaging Breaks Barriers in Complex Media for Biomedical Use
Researchers developed a physics-based machine learning imaging system that enhances visibility through complex media, holding promise for biomedical imaging.
•EurekAlert
AI Model Accelerates Accurate Dose Prediction for CyberKnife Radiotherapy
A physics- and spatially informed diffusion model accelerates Monte Carlo–level dose estimation for CyberKnife radiotherapy using planning CT and anatomical data.
•EurekAlert
New G-AUDIT Tool Detects Hidden Bias in Medical AI Training Data
Johns Hopkins and FDA researchers unveil G-AUDIT, a tool to identify hidden biases in medical AI datasets before model training.